{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:30:10Z","timestamp":1794274210079,"version":"4.9.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013061","name":"Jilin Scientific and Technological Development Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Medicine"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.clinme.2024.100252","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T23:29:15Z","timestamp":1727825355000},"page":"100252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Dynamics of minimal residual disease and its clinical implications in multiple myeloma: A retrospective real-life analysis"],"prefix":"10.1016","volume":"24","author":[{"given":"Weiling","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2575-5305","authenticated-orcid":false,"given":"Xinyue","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6594-1851","authenticated-orcid":false,"given":"Xingcheng","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengru","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maozhuo","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengtuan","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufeng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xintian","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2285-0818","authenticated-orcid":false,"given":"Yun","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2288-556X","authenticated-orcid":false,"given":"Fengyan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.clinme.2024.100252_bib0001","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41571-018-0018-y","article-title":"The multiple myelomas \u2014 current concepts in cytogenetic classification and therapy","volume":"15","author":"Kumar","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"19","key":"10.1016\/j.clinme.2024.100252_bib0002","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1158\/1078-0432.CCR-21-1059","article-title":"Minimal residual disease in myeloma: application for clinical care and new drug registration","volume":"27","author":"Anderson","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinme.2024.100252_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100732","article-title":"Defining the undetectable: the current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity","volume":"46","author":"Diamond","year":"2021","journal-title":"Blood Rev"},{"issue":"18","key":"10.1016\/j.clinme.2024.100252_bib0004","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1182\/blood.2023020284","article-title":"Potential future direction of measurable residual disease evaluation in multiple myeloma","volume":"142","author":"Mohty","year":"2023","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clinme.2024.100252_bib0005","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.clinme.2024.100252_bib0006","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1038\/bmt.2016.222","article-title":"Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta analysis","volume":"51","author":"Landgren","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.clinme.2024.100252_bib0007","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.clinme.2024.100252_bib0008","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/j.clml.2019.09.622","article-title":"Minimal residual disease status as a surrogate endpoint for progression-free survival in newly diagnosed multiple myeloma studies: A meta-analysis","volume":"20","author":"Avet-Loiseau","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"23","key":"10.1016\/j.clinme.2024.100252_bib0009","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clinme.2024.100252_bib0010","series-title":"Hematologic malignancies: Regulatory Considerations For Use of Minimal Residual Disease in Development of Drug and Biological Products For Treatment - Guidance for Industry","year":"2020"},{"key":"10.1016\/j.clinme.2024.100252_sbref0011","series-title":"Guideline On the Use of Minimal Residual Disease As Aclinical Endpoint in Multiple Myeloma Studies","year":"2018"},{"issue":"8","key":"10.1016\/j.clinme.2024.100252_bib0012","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1200\/JCO.19.01231","article-title":"Measurable residual disease by next-generation flow cytometry in multiple myeloma","volume":"38","author":"Paiva","year":"2020","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.clinme.2024.100252_bib0013","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clinme.2024.100252_bib0014","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood.2020006731","article-title":"Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma","volume":"137","author":"Goicoechea","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clinme.2024.100252_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2020.101149","article-title":"Monitoring minimal residual disease in the bone marrow using next generation sequencing","volume":"33","author":"Rustad","year":"2020","journal-title":"Best Pract Res Clin Haematol"},{"issue":"15","key":"10.1016\/j.clinme.2024.100252_bib0016","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.1158\/1078-0432.CCR-16-2895","article-title":"The role of minimal residual disease testing in myeloma treatment selection and drug development: current value and future applications","volume":"23","author":"Anderson","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.clinme.2024.100252_bib0017","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood.2022016782","article-title":"MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials","volume":"141","author":"Paiva","year":"2023","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.clinme.2024.100252_bib0018","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clinme.2024.100252_bib0019","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next generation flow for highly sensitive and standardised detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clinme.2024.100252_bib0020","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41375-020-01012-4","article-title":"International harmonisation in performing and reporting minimal residual disease assessment in multiple myeloma trials","volume":"35","author":"Costa","year":"2021","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.clinme.2024.100252_bib0021","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.clinme.2024.100252_bib0022","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2016-03-705319","article-title":"Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients","volume":"127","author":"Paiva","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clinme.2024.100252_bib0023","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13045-021-01135-w","article-title":"Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma","volume":"14","author":"Martinez\u2011Lopez","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clinme.2024.100252_bib0024","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1002\/acg2.26","article-title":"Meeting report: advances in minimal residual disease testing in multiple myeloma 2018","volume":"2","author":"Landgren","year":"2019","journal-title":"Adv Cell Gene Ther"},{"issue":"15","key":"10.1016\/j.clinme.2024.100252_bib0025","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.clinme.2024.100252_bib0026","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.clinme.2024.100252_bib0027","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1200\/JCO.2012.46.2119","article-title":"Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study","volume":"31","author":"Rawstron","year":"2013","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.clinme.2024.100252_bib0028","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2016.69.2517","article-title":"Depth of response in multiple myeloma: a pooled analysis of three PETHEMA\/GEM clinical trials","volume":"35","author":"Lahuerta","year":"2017","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clinme.2024.100252_bib0029","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.3324\/haematol.2018.202200","article-title":"Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients","volume":"104","author":"Jones","year":"2019","journal-title":"Haematologica"},{"issue":"20","key":"10.1016\/j.clinme.2024.100252_bib0030","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1182\/blood-2014-11-568907","article-title":"New criteria for response assessment: role of minimal residual disease in multiple myeloma","volume":"125","author":"Paiva","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clinme.2024.100252_bib0031","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/joim.12590","article-title":"Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes","volume":"281","author":"Landgren","year":"2017","journal-title":"J Intern Med"},{"issue":"4","key":"10.1016\/j.clinme.2024.100252_bib0032","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.2020010439","article-title":"Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE","volume":"139","author":"San-Miguel","year":"2022","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.clinme.2024.100252_bib0033","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clinme.2024.100252_bib0034","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41408-017-0028-5","article-title":"MRD in multiple myeloma: more questions than answers?","volume":"7","author":"Moreau","year":"2017","journal-title":"Blood Cancer J"},{"issue":"14","key":"10.1016\/j.clinme.2024.100252_bib0035","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/bloodadvances.2020002037","article-title":"Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma","volume":"4","author":"Martinez-Lopez","year":"2020","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.clinme.2024.100252_bib0036","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1001\/jamaoncol.2018.5457","article-title":"Remission and progression-free survival in patients with newly diagnosed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone: five-year follow-up of a phase 2 clinical trial","volume":"4","author":"Kazandjian","year":"2018","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.clinme.2024.100252_bib0037","doi-asserted-by":"crossref","first-page":"E61","DOI":"10.1002\/ajh.26810","article-title":"Dynamic monitoring of minimal residual disease in newly-diagnosed multiple myeloma","volume":"98","author":"Yang","year":"2023","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.clinme.2024.100252_bib0038","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/j.clml.2019.09.069","article-title":"Sequential minimal residual disease (MRD) monitoring: Results from the UK Myeloma XI trial","volume":"19","author":"de Tute","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.clinme.2024.100252_bib0039","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","article-title":"Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial","volume":"20","author":"Jackson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.clinme.2024.100252_bib0040","doi-asserted-by":"crossref","first-page":"e422","DOI":"10.1016\/S2352-3026(21)00130-7","article-title":"Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial","volume":"8","author":"Diamond","year":"2021","journal-title":"Lancet Hematol"},{"issue":"1","key":"10.1016\/j.clinme.2024.100252_bib0041","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/hematology.2021000230","article-title":"Minimal residual disease in multiple myeloma: why, when, where","volume":"2021","author":"Yee","year":"2021","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"25","key":"10.1016\/j.clinme.2024.100252_bib0042","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1200\/JCO.21.02228","article-title":"Minimal residual disease after autologous stem-cell transplant for patients with myeloma: prognostic significance and the impact of lenalidomide maintenance and molecular risk","volume":"40","author":"de Tute","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clinme.2024.100252_bib0043","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1182\/blood.2020008090","article-title":"Undetectable MRD can change the deal","volume":"137","author":"Corre","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clinme.2024.100252_bib0044","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13045-020-00911-4","article-title":"Measurable residual disease in multiple myeloma: ready for clinical practice?","volume":"13","author":"Burgos","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"7","key":"10.1016\/j.clinme.2024.100252_bib0045","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood.2023022083","article-title":"Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma","volume":"143","author":"Guerrero","year":"2024","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clinme.2024.100252_bib0046","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1182\/blood.2023022080","article-title":"Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma","volume":"143","author":"D'Agostino","year":"2024","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.clinme.2024.100252_bib0047","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1182\/blood.2022019531","article-title":"Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma","volume":"142","author":"Rosi\u00f1ol","year":"2023","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clinme.2024.100252_bib0048","doi-asserted-by":"crossref","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","article-title":"Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial","volume":"10","author":"Costa","year":"2023","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1016\/j.clinme.2024.100252_bib0049","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s11912-024-01537-2","article-title":"Minimal residual disease-adapted therapy in multiple myeloma: current evidence and opinions","volume":"26","author":"Meseha","year":"2024","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"10.1016\/j.clinme.2024.100252_bib0050","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.hoc.2023.12.009","article-title":"Measurable residual disease and decision-making in multiple myeloma","volume":"38","author":"Derman","year":"2024","journal-title":"Hematol Oncol Clin North Am"},{"issue":"23","key":"10.1016\/j.clinme.2024.100252_bib0051","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1182\/blood.2022016170","article-title":"MRD in multiple myeloma: does CR really matter?","volume":"140","author":"Paiva","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clinme.2024.100252_bib0052","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/ajh.25481","article-title":"Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy","volume":"94","author":"Tschautscher","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clinme.2024.100252_bib0053","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102016","article-title":"Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing","volume":"60","author":"Oliva","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"Suppl 1","key":"10.1016\/j.clinme.2024.100252_bib0054","first-page":"435","article-title":"Minimal residual disease in multiple myeloma: final analysis of the IFM2009 trial","volume":"130","author":"Avet-Loiseau","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clinme.2024.100252_bib0055","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1093\/ajcp\/aqab163","article-title":"VS38c and CD38-multiepitope antibodies provide highly comparable minimal residual disease data in patients with multiple myeloma","volume":"157","author":"Broijl","year":"2022","journal-title":"Am J Clin Pathol"}],"container-title":["Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147021182405437X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147021182405437X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T18:46:47Z","timestamp":1732733207000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S147021182405437X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S147021182405437X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinme.2024.100252","relation":{},"ISSN":["1470-2118"],"issn-type":[{"value":"1470-2118","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dynamics of minimal residual disease and its clinical implications in multiple myeloma: A retrospective real-life analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinme.2024.100252","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of Royal College of Physicians.","name":"copyright","label":"Copyright"}],"article-number":"100252"}}